<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Epigenetic gene silencing is an important mechanism in the initiation and progression of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Abnormal DNA CpG island hypermethylation and <z:chebi fb="0" ids="15358">histone</z:chebi> modifications are involved in aberrant silencing of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e>-suppressor genes </plain></SENT>
<SENT sid="2" pm="."><plain>LSD1 (lysine-specific demethylase 1) was the first enzyme identified to specifically demethylate H3K4 (Lys(4) of <z:chebi fb="0" ids="15358">histone</z:chebi> H3) </plain></SENT>
<SENT sid="3" pm="."><plain>Methylated H3K4 is an important mark associated with transcriptional activation </plain></SENT>
<SENT sid="4" pm="."><plain>The <z:chebi fb="0" ids="24040">flavin adenine dinucleotide</z:chebi>-binding <z:chebi fb="39" ids="32952">amine</z:chebi> oxidase domain of LSD1 is homologous with two <z:chebi fb="0" ids="51349">polyamine</z:chebi> oxidases, SMO (<z:chebi fb="0" ids="15746">spermine</z:chebi> oxidase) and APAO (N(1)-acetylpolyamine oxidase) </plain></SENT>
<SENT sid="5" pm="."><plain>We have demonstrated previously that long-chain <z:chebi fb="0" ids="51349">polyamine</z:chebi> analogues, the oligoamines, are inhibitors of LSD1 </plain></SENT>
<SENT sid="6" pm="."><plain>In the present paper we report the synergistic effects of specific oligoamines in combination with DFMO (2-difluoromethylornithine), an inhibitor of <z:chebi fb="0" ids="18257">ornithine</z:chebi> decarboxylase, in human <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cells </plain></SENT>
<SENT sid="7" pm="."><plain>DFMO treatment depletes natural <z:chebi fb="0" ids="51349">polyamines</z:chebi> and increases the uptake of exogenous <z:chebi fb="0" ids="51349">polyamines</z:chebi> </plain></SENT>
<SENT sid="8" pm="."><plain>The combination of oligoamines and DFMO results in a synergistic re-expression of aberrantly silenced <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e>-suppressor genes, including SFRP2 (secreted frizzled-related protein 2), which encodes a Wnt signalling pathway <z:chebi fb="68" ids="48706">antagonist</z:chebi> and plays an anti-tumorigenic role in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>The treatment-induced re-expression of SFRP2 is associated with increased H3K4me2 (di-<z:chebi fb="36" ids="29309">methyl</z:chebi> H3K4) in the gene promoter </plain></SENT>
<SENT sid="10" pm="."><plain>The combination of LSD1-inhibiting oligoamines and DFMO represents a novel approach to epigenetic therapy of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
</text></document>